

Title (en)
COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND INFLAMMATION IN DOGS

Title (de)
COX-2 SELEKTIVES CARPROFEN ZUR BEHANDLUNG VON SCHMERZ UND ENTZUENDUNG BEI HUNDEN

Title (fr)
CARPROFENE INHIBANT SELECTIVEMENT COX-2 ET UTILISE DANS LE TRAITEMENT DE LA DOULEUR ET DES INFLAMMATIONS CHEZ LES CHIENS

Publication
EP 0988034 A1 20000329 (EN)

Application
EP 98915041 A 19980501

Priority
• IB 9800662 W 19980501
• US 4563597 P 19970505

Abstract (en)
[origin: WO9850033A1] Treating or preventing inflammatory processes and diseases in dogs associated with the activity of inducible cyclo-oxygenase-2 (COX-2), while at the same time reducing or eliminating undesirable side effects associated with simultaneous inhibition of the activity of constitutive cyclo-oxygenase-1 (COX-1) by selectively inhibiting COX-2 activity with reference to COX-1 activity, wherein the selectivity ratio or COX-2 : COX-1 activity inhibition is at least 3 : 1 based on ex vivo inhibition levels measured in whole blood; the inhibitor is a member selected from the group of anti-inflammatory compounds consisting essentially of salicylic acid derivatives, p-aminophenol derivatives, indole and indene acetic acids, heteroaryl acetic acids, arylpropionic acids, anthranilic acids, enolic acids, and alkanones; the inhibitor in particular is comprised of (+)(S)-enantiomer of 6-chloro- alpha -methyl-9H-carbazole-2-acetic acid.

IPC 1-7
A61K 31/40

IPC 8 full level
A61K 31/40 (2006.01); **A61K 31/403** (2006.01); **A61P 29/00** (2006.01); **A61P 43/00** (2006.01); **C07D 209/88** (2006.01)

CPC (source: EP KR)
A61K 31/40 (2013.01 - EP KR); **A61P 29/00** (2018.01 - EP); **A61P 43/00** (2018.01 - EP)

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)
WO 9850033 A1 19981112; AP 9801234 A0 19991104; AR 011726 A1 20000830; AR 039628 A2 20050302; AU 6932198 A 19981127; BG 103852 A 20000630; BR 9808720 A 20000711; CA 2288759 A1 19981112; CN 1255059 A 20000531; DZ 2479 A1 20030201; EA 003696 B1 20030828; EA 199900895 A1 20000626; EP 0988034 A1 20000329; GT 199800063 A 19991026; HR P980244 A2 19990228; HU P0001286 A2 20001128; HU P0001286 A3 20001228; ID 21311 A 19990520; IL 132570 A0 20010319; IS 5220 A 19991019; JP 2000513020 A 20001003; KR 20010012300 A 20010215; KR 20040004406 A 20040113; MA 26491 A1 20041220; NO 995389 D0 19991104; NO 995389 L 20000104; NZ 500183 A 20020426; OA 11213 A 20030714; PA 8450601 A1 20000524; PE 72599 A1 19990812; PL 337003 A1 20000731; SK 148199 A3 20010911; TN SN98059 A1 20050315; TW 590773 B 20040611; UY 24989 A1 20011025; YU 55899 A 20030829; ZA 983722 B 19991104

DOCDB simple family (application)
IB 9800662 W 19980501; AP 9801234 A 19980504; AR P030101251 A 20030409; AR P980102089 A 19980505; AU 6932198 A 19980501; BG 10385299 A 19991103; BR 9808720 A 19980501; CA 2288759 A 19980501; CN 98804845 A 19980501; DZ 980089 A 19980302; EA 199900895 A 19980501; EP 98915041 A 19980501; GT 199800063 A 19980504; HR P980244 A 19980505; HU P0001286 A 19980501; ID 980651 A 19980501; IL 13257098 A 19980501; IS 5220 A 19991019; JP 54786998 A 19980501; KR 19997010252 A 19991105; KR 20037005258 A 20030414; MA 25059 A 19980504; NO 995389 A 19991104; NZ 50018398 A 19980501; OA 9900242 A 19991102; PA 8450601 A 19980505; PE 00033598 A 19980504; PL 33700398 A 19980501; SK 148199 A 19980501; TN SN98059 A 19980504; TW 87106689 A 19980430; UY 24989 A 19980504; YU 55899 A 19980501; ZA 983722 A 19980504